Cost effectiveness analysis of pneumococcal vaccination of older people in France;Etude coût-efficacité de la vaccination pneumococcique chez les personnes âgées en France

Medecine et Maladies Infectieuses

Volumn 32, Issue 8, 2002, Pages 405-417

  Amazian, K ^a   Nicoloyannis, N ^a   Colin, C ^a,b   Nguyen, V H ^c   Duru, G ^a  

^a CNRS   (France)

^b HOSPICES CIVILS DE LYON   (France)

^c Gouvernement du Quebec   (Canada)

Author keywords

Cost effectiveness; Streptococcus pneumoniae; Vaccine

Indexed keywords

ANTIBIOTIC AGENT; INFLUENZA VACCINE; PNEUMOCOCCUS VACCINE;

AGED; AGING; ANTIBIOTIC THERAPY; ARTICLE; COST EFFECTIVENESS ANALYSIS; FRANCE; HEALTH CARE COST; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MORTALITY; PROBABILITY; STREPTOCOCCUS INFECTION; STREPTOCOCCUS PNEUMONIAE; VACCINATION;

EID: 0036694294     PISSN: 0399077X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0399-077X(02)00393-1     Document Type: Article

References (35)

1. Aszkenasy DM, George RC, Begg NT. Pneumococcal bacteraemia and meningitis in England and Wales 1982 to 1992. CDR Review 1995;5:R45-50.
2. Plouffe JF, Breiman RF, Facklam RR, for the Franklin County Pneumonia Study Group. Bacteremia with Streptococcus pneumoniae. Implications for therapy and prevention. JAMA 1996;275:194-8.
3. Bennett NM, Buffington J, LaForce FM. Pneumococcal bacteremia in Monroe County, New York. Am J Public Health 1992;18:1513-6.
4. Léophonte P, Catinaud F, Rouquet RM, Thach KS, Lemozy J, Larios-Ramos L, et al. La pneumonie à pneumocoque. Etude rétrospective de 79 cas. Méd et Hyg 1988;46:3541-6.
5. Kramer MR, Rudensky B, Hadas-Halperin I, Isacshon M, Melzer E. Pneumococcal bacteremia - no change in mortality in 30 years: analysis of 104 cases and review of the literature. Israel J Med Sci 1987;23:174-80.
6. Beytout J, Travade Ph, Labbé A, Pezet D. Les infections chez les splénectomisés. La lettre de l'infectiologue 1990;5:351-9.
7. Centers for Disease Control. Recommendations of the Immunization Practices Advisory Committee (ACIP). Prevention of Pneumococcal Disease. MMWR 1997;46:1-24.
8. Gaillat J. Epidémiologie des infections systémiques à Streptococcus pneumoniae. Presse Med 1998;27:S9-S16.
9. Geslin P, Fremaux A, Sissia G, Spicq C. Streptococcus pneumoniae: sérotypes, souches invasives et résistantes aux antibiotiques. Situation actuelle en France. Presse Med 1998;27:S21-7.
10. Austrian R, Douglan RM, Schiffman G, Coetzee AM, Koornhof HJ, Hayden-Smith S, et al. Prevention of pneumococcal pneumonia by vaccination. Trans Assoc Am Physicians 1976;89:184-9.
11. Gaillat J, Zmirou D, Mallaret MR, Rouhan D, Bru JP, Stahl JP, et al. Essai clinique du vaccin antipneumococcique chez des personnes âgées vivant en institution. Rev Epidém Santé Publ 1985;33:437-44.
12. Simberkoff MS, Cross AP, Al-Ibrahim M, Baltch AL, Geiseler PJ, Nadler J, et al. Efficacy of pneumococcal vaccine in high-risk patients: results of a veterans administration cooperative study. N Engl J Med 1986;315:1318-27.
13. Koivula I, Stén M, Leinonen M, Mäkelä PH. Clinical efficacy of pneumococcal vaccine in the elderly: a randomised, single-blind population-based trial. Am J Med 1997;103:281-90.
14. Örtqvist A, Hedlund J, Burman LA, Elbel E, Höfer M, Leinonen M, et al. Randomised trial of 23-valent pneumococcal capsular polysaccharide vaccine in prevention of pneumonia in middle-aged and elderly people. Lancet 1998;351:399-403.
15. Gable CB, Holzer SS, Engelhart L, Friedman RB, Smeltz F, Schroeder D, et al. Pneumococcal vaccine. Efficacy and associated cost savings. JAMA 1990;264:2910-5.
16. Bolan G, Broome CV, Facklam RR, Plikaytis BD, Fraser DW, Schlech WF. Pneumococcal vaccine efficacy in selected populations in the United States. Ann Intern Med 1986;104:1-6.
17. Butler JC, Breiman RF, Campbell JF, Lipman HB, Broome CV, Facklam RR. Pneumococcal polysaccharide vaccine efficacy. An evaluation of current recommendations. JAMA 1993;270:1826-31.
18. Sims RV, Steinmann WC, McConville JH, King LR, Zwick WC, Schwartz JS. The clinical effectiveness of pneumococcal vaccine in the elderly. Ann Intern Med 1988;108:653-7.
19. Shapiro ED, Berg AT, Austrian R, Schroeder D, Parcells V, Margolis A, et al. The protective efficacy of polyvalent pneumococcal polysaccharide vaccine. N Engl J Med 1991;325:1453-60.
20. Farr BM, Johnston BL, Cobb DK, Fisch MJ, Germanson TP, Adal KA, et al. Preventing pneumococcal bacteremia in patients at risk: results of a matched case-control study. Arch Intern Med 1995;155:2336-40.
21. Fine MJ, Smith MA, Carson CA, Meffe F, Sankey SS, Weissfeld LA, et al. Efficacy of pneumococcal vaccination in adults. A meta-analysis of randomized controlled trials. Arch Intern Med 1994;154:2666-77.
22. Hutchison BG, Oxman AD, Shannon HS, Lloyd S, Altmayer CA, Thomas K. Clinical effectiveness of pneumococcal vaccine. Meta-analysis. Can Fam Physician 1999;45:2381-93.
23. Holzer SS, Gable CB, Freidman RB. Cost-effectiveness of pneumococcal vaccine: implications for managed care. J Res Pharma Eco 1993;5(1):79-95.
24. Jiémenez FJ, Guallar P, Rubio C, Villasante P, Guallar E. Cost-effectiveness analysis of pneumococcal vaccination in the elderly Spanish population. Br J Med Eco 1996;10:193-202.
25. Office canadien de coordination de l'évaluation des technologies de la santé. Lignes directrices pour l'évaluation économique des produits pharmaceutiques: Canada, second ed., Ottawa: Office canadien de coordination de l'évaluation des technologies de la santé (OCCETS). 1998.
26. Ament A, Baltussen R, Duru G, Rigaud-Bully C, Graeve de D, Örtqvist A, et al. Cost-effectiveness of pneumococcal vaccination of older people: a study in 5 western European countries. Clin Infect Dis 2000;31:444-50.
27. Fedson DS, Soubeyrand B. Généralisation de la vaccination pneumococcique dans les pays industrialisés. La France se joindra-t-elle au mouvement? Presse Med 1998;27:S50-4.
28. Nichol KL, Baken L, Wuorenma J, Nelson A. The health and economic benefits associated with pneumococcal vaccination of elderly persons with chronic lung disease. Arch Intern Med 1999;159:2437-42.
29. Christenson B, Lundbergh P, Hedlund J, Örtqvist A. Effects of a large-scale intervention with influenza and 23-valent pneumococcal vaccines in adults aged 65 years or older: a prospective study. Lancet 2001;357:1008-11.
30. Sisk JE, Riegelman RK. Cost effectiveness of vaccination against pneumococcal pneumonia: an update. Ann Intern Med 1986;104:79-86.
31. Baltussen R, Ament R, Leidl R, Van Furth R. Cost-effectiveness of vaccination against pneumococcal pneumonia in The Netherlands. Eur J Public Health 1997;7:153-61.
32. Sisk JE, Moskowitz AJ, Whang W, Lin JD, Fedson DS, McBean AM, et al. Cost effectiveness of vaccination against pneumococcal bacteremia among elderly people. JAMA 1997;278:1333-9.
33. Sisk JE, Sanders CR, Riddiough MA, Bell JC. Cost effectiveness of vaccination against pneumococcal pneumonia. N Engl J Med 1980;303:553-9.
34. Plans Rubio P, Garrido Morales P, Salleras Sanmarti L. The cost effectiveness of pneumococcal vaccination in Catalonia. Rev Esp Salud Pûblica 1995;69:409-17.
35. Patrick KM, Woolley FR. A cost-benefit analysis of immunization for pneumococcal pneumonia. JAMA 1981;245:473-7.